Verona Pharma Announces Publication of Key Paper on RPL554 in COPD in the European Respiratory Journal
September 06, 2018 02:00 ET
|
Verona Pharma plc
LONDON, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and...
Verona Pharma plc : PDMR Dealing & Issue of Shares
August 10, 2018 07:12 ET
|
Verona Pharma plc
LONDON, Aug. 10, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2018
August 07, 2018 02:00 ET
|
Verona Pharma plc
Significant progress with RPL554 as potential treatment for COPD and CF Recently initiated important Phase 2 trial as add-on to dual bronchodilator therapy for COPD maintenance treatment LONDON,...
Verona Pharma Initiates Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment
August 01, 2018 02:00 ET
|
Verona Pharma plc
This three-way crossover study will inform design of pivotal Phase 3 trials Top line data expected first quarter 2019 LONDON, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP)...
Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2018 and Provide Clinical Development Update
July 26, 2018 08:30 ET
|
Verona Pharma plc
LONDON, July 26, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona Pharma to Present at 2018 Wedbush PacGrow Healthcare Conference
July 24, 2018 08:30 ET
|
Verona Pharma plc
LONDON, July 24, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona Pharma to Present at Upcoming Investor Conferences
May 30, 2018 08:30 ET
|
Verona Pharma plc
LONDON, May 30, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona Pharma Files Shelf Registration Statement with SEC
May 23, 2018 02:00 ET
|
Verona Pharma plc
LONDON, May 23, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and...
Verona Pharma Presented Clinical Data at ATS 2018 that Further Highlights RPL554 as a First-in-Class Treatment for COPD
May 21, 2018 17:15 ET
|
Verona Pharma plc
LONDON, May 21, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or “the Company”), a clinical-stage biopharmaceutical company focused on developing and...
Verona Pharma to Present Clinical Trial Data of RPL554 for COPD Maintenance Treatment at American Thoracic Society 2018 International Conference
May 09, 2018 08:30 ET
|
Verona Pharma plc
LONDON, May 09, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...